ALX Oncology Holdings Inc is a clinical-stage biopharmaceutical company that focuses on developing targeted therapies for the treatment of cancer. The company was founded in 2015 and is headquartered in Burlingame, California, USA. ALX Oncology is dedicated to addressing the unmet medical needs of cancer patients by advancing novel therapies that target immune checkpoint pathways and other mechanisms involved in cancer growth and progression.
ALX Oncology's main focus is on developing therapies that modulate the CD47-SIRPα pathway, which plays a crucial role in immune evasion by cancer cells. Their lead product candidate, ALX148, is an investigational CD47-blocking therapeutic designed to enhance the body's immune response against cancer. The company believes that targeting this pathway can potentially improve the efficacy of existing cancer treatments and provide new treatment options for patients.
ALX Oncology collaborates with various research institutions and partners to conduct clinical trials and gather data on the safety and efficacy of their investigational therapies. Clinical trials are essential for demonstrating the potential benefits of their treatments and obtaining regulatory approvals for their use in patients.